Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.

Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma.

Glioblastoma (GBM) is a common brain tumour in adults, which, despite multimodality treatment, has a poor median survival. Efficacy of therapy is assessed by clinical examination and magnetic resonance imaging (MRI) features. There is now a recognised subset of treated patients with imaging features that indicate "progressive disease" according to Macdonald's criteria, but subsequently, show st...

Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial

BACKGROUND Standard therapy for Glioblastoma multiforme (GBM) involves maximal safe tumor resection followed with radiotherapy and concurrent adjuvant temozolomide. About 20 to 30% patients undergoing their first post-radiation MRI show increased contrast enhancement which eventually recovers without any new treatment. This phenomenon is referred to as pseudoprogression. Differentiating tumor p...

Treatment-related brain tumor imaging changes: So-called “pseudoprogression” vs. tumor progression: Review and future research opportunities

BACKGROUND Glioblastoma multiforme (GBM) has a dismal prognosis despite aggressive therapy. Initial diagnosis and measurement of response to treatment is usually determined by measurement of gadolinium-enhanced tumor volume with magnetic resonance imaging (MRI). Unfortunately, many GBM treatment modalities can cause changes in tumor gadolinium enhancement patterns that mimic tumor progression. ...

Progression or Pseudoprogression? A Review of Post- Treatment MRI Appearances of Glioblastoma

Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients

Pseudoprogression is regarded as a subacute form of treatment-related change with a reported incidence of 20-30%, occurring predominantly within the first three months after the completion of concurrent chemoradiotherapy (CCRT) in glioblastoma multiforme (GBM) patients. Occurrence of progressive lesions on conventional contrast-enhanced MR imaging may also accompany clinical deterioration, posi...